ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB

Bill Sasiela,Christelle Lorenzato,Kathryn Miller,John J P Kastelein,Jennifer G Robinson,Michel Farnier,Umesh Chaudhari

Journal of the American College of Cardiology（2015）

引用 7|浏览42

暂无评分

摘要

Alirocumab added to statin therapy has shown robust reductions in low-density lipoprotein cholesterol (LDL-C) and can also reduce it to very low levels. Consequences of very low LDL-C levels are not well understood. Therefore, AE rates were examined in patients (pts) who achieved 2 consecutive

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要